Corona Remedies Share Price in Focus; Receives Brazil GMP Certification for Two Manufacturing Units

Corona Remedies Limited has received Good Manufacturing Practice (GMP) compliance certification from Brazil’s health regulatory agency, ANVISA, for two manufacturing facilities in Bhayla, Ahmedabad, Gujarat. 

The certification covers the company’s oral solid dosage (OSD) manufacturing facility and its hormone manufacturing facility. The company announced the development in a filing dated 22 October 2026. 

Certification Covers OSD and Hormone Manufacturing 

The two facilities covered by the certification manufacture different types of pharmaceutical products. The OSD facility handles oral solid dosage products, while the other unit is used for hormone manufacturing. 

The company’s filing confirms that ANVISA has issued GMP compliance certification for both facilities. However, it does not provide details of the products covered under the certification or specify the requirements assessed by the Brazilian regulator. 

No Details on Exports or Financial Impact 

The announcement does not state whether the certification is linked to plans to supply medicines to Brazil or whether it will lead to new export orders. It also does not mention any changes to production capacity at the two Ahmedabad facilities. 

Corona Remedies has not provided an estimate of the certification’s expected contribution to revenue or any other financial impact in the filing. Details regarding the validity period of the certification have also not been disclosed. 

The filing confirms the certification received by the two manufacturing units but does not outline any further operational plans arising from the development. 

Read More: Zee Entertainment Appoints Suraj Singh as Zee Studios Business Head! 

Corona Remedies Share Price Performance  

As of October 22, 2026, 1:00 pm, Corona Remedies share price was trading at ₹2,031.30, a 0.51% increase from the previous closing price. 

Conclusion 

Corona Remedies has received ANVISA GMP compliance certification for its oral solid dosage and hormone manufacturing facilities in Bhayla, Ahmedabad.  

The company’s filing dated 22 October 2026 confirms the certification for both units but provides no further details on its commercial implications. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.